全文获取类型
收费全文 | 758062篇 |
免费 | 52885篇 |
国内免费 | 1432篇 |
专业分类
耳鼻咽喉 | 9649篇 |
儿科学 | 24666篇 |
妇产科学 | 18572篇 |
基础医学 | 117213篇 |
口腔科学 | 20866篇 |
临床医学 | 69610篇 |
内科学 | 144246篇 |
皮肤病学 | 16877篇 |
神经病学 | 53947篇 |
特种医学 | 27771篇 |
外国民族医学 | 76篇 |
外科学 | 113058篇 |
综合类 | 15540篇 |
现状与发展 | 2篇 |
一般理论 | 213篇 |
预防医学 | 56681篇 |
眼科学 | 17498篇 |
药学 | 57746篇 |
4篇 | |
中国医学 | 2407篇 |
肿瘤学 | 45737篇 |
出版年
2021年 | 6494篇 |
2019年 | 6428篇 |
2018年 | 9050篇 |
2017年 | 7006篇 |
2016年 | 7761篇 |
2015年 | 8676篇 |
2014年 | 11920篇 |
2013年 | 17710篇 |
2012年 | 24014篇 |
2011年 | 25099篇 |
2010年 | 14687篇 |
2009年 | 13677篇 |
2008年 | 23138篇 |
2007年 | 24906篇 |
2006年 | 25202篇 |
2005年 | 23660篇 |
2004年 | 22999篇 |
2003年 | 21770篇 |
2002年 | 21131篇 |
2001年 | 37095篇 |
2000年 | 37625篇 |
1999年 | 31125篇 |
1998年 | 8465篇 |
1997年 | 7137篇 |
1996年 | 7421篇 |
1995年 | 7112篇 |
1994年 | 6503篇 |
1993年 | 5962篇 |
1992年 | 23440篇 |
1991年 | 23334篇 |
1990年 | 22778篇 |
1989年 | 22496篇 |
1988年 | 20424篇 |
1987年 | 19756篇 |
1986年 | 18810篇 |
1985年 | 17682篇 |
1984年 | 13034篇 |
1983年 | 11008篇 |
1982年 | 6155篇 |
1979年 | 11733篇 |
1978年 | 8339篇 |
1977年 | 7008篇 |
1976年 | 6771篇 |
1975年 | 7429篇 |
1974年 | 8692篇 |
1973年 | 8311篇 |
1972年 | 7835篇 |
1971年 | 7272篇 |
1970年 | 7049篇 |
1969年 | 6460篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Amosova E. N. Shilova I. V. Zueva E. P. Rybalkina O. Yu. 《Pharmaceutical Chemistry Journal》2020,54(7):721-724
Pharmaceutical Chemistry Journal - Three extracts were produced from the above-ground part of the meadowsweet Filipendula ulmaria (L.) Maxim. using water, 40% ethanol, and 70% ethanol. Comparative... 相似文献
13.
Koel Dutt P N Agarwal Rajdeep Singh Vikas Singh Tomar 《The Indian journal of surgery》2015,77(1):62-64
Haemophilia is a common cause of genetically inherited bleeding disorders. Pseudotumours occur in 1–2 % of persons with severe forms of haemophilia. These are a result of repeated haemorrhage into soft tissues, subperiosteum or a site of bone fracture with inadequate resorption of the extravasated blood. There are a number of therapeutic alternatives for this dangerous condition: surgical removal, percutaneous management, irradiation, embolization etc. In this case report, we describe the natural history, clinical course and successful surgical management of a patient with haemophilia who presented with a massive pseudotumour. We also briefly review the relevant literature on the various therapeutic modalities that have been implemented in the management of this rare complication. Though surgeons may be averse to operate on haemophiliacs, primary surgical management as done in our case may prove to be the definitive treatment option for such patients. 相似文献
14.
15.
16.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
17.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
18.
19.
Context Withania somnifera (L.) Dunal is traditionally used for treating various ailments, but lacks scientific evaluation.Objective This study evaluates Withania somnifera (WS) for its effect on platelet activity and inflammatory enzymes.Materials and methods Aqueous and ethanolic (1:1) leaf extracts were subjected to in vitro indirect haemolytic activity using Naja naja venom, human platelet aggregation was quantified for lipid peroxidation using arachidonic acid (AA) as agonist and 5-lipoxygenase (5-LOX) levels were determined using standard spectrometric assays. Further, molecular docking was performed by the ligand fit method using molegro software package (Molegro ApS, Aarhus, Denmark).Results The study found that aqueous and ethanol extracts have very negligible effect (15%) with an IC50 value of 13.8?mg/mL on PLA2 from Naja naja venom. Further, extracts of WS also had very little effect (18%) with an IC50 value of 16.6?mg/mL on malondialdehyde (MDA) formation. However, a 65% inhibition of 5-LOX with an IC50 value of 0.92?mg/mL was observed in 1:1 ethanol extracts. The same was evident from SAR model with the active ingredient withaferin A binding predominantly on Phe 77, Tyr 98, Arg 99, Asp 164, Leu 168, Ser 382, Arg 395, Tyr 396 and Tyr 614 with an atomic contact energy value of??128.96 compared to standard phenidone (?103.61). Thus, the current study validates the application of WS for inflammatory diseases.Conclusion This study reveals the inhibitory potential of W. somnifera on inflammatory enzymes and platelet aggregation. Thus, WS can serve as a newer, safer and affordable medicine for inflammatory diseases. 相似文献
20.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)